Inovio Pharmaceuticals (INO) 9.09 $INO
Inovio Pharmaceuticals, Inc. (INO) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:32AM CDT
Inovio Pharmaceuticals, Inc. (INO) was a big mover last session, as the company saw its shares rise more nearly 13% on the day.
INO: 9.09 (-0.36), ACOR: 34.74 (-0.39)
Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day
GlobeNewswire - Thu Mar 19, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Chief Operating Officer, Dr. Niranjan Sardesai, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 at the Metropolitan Club in New York City.
INO: 9.09 (-0.36)
Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development -- Infectious Diseases
GlobeNewswire - Wed Mar 18, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today the appointment of Scott M. White, M.D. as Vice President, Clinical Development - Infectious Diseases. Dr. White will be responsible for advancing Inovio's infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
INO: 9.09 (-0.36)
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 17, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
PCYO: 5.04 (-0.21), INO: 9.09 (-0.36), PRSC: 50.00 (-0.72), GLMD: 13.25 (+1.60), ICEL: 7.71 (-0.39), BDE: 9.99 (+0.17), NERV: 5.98 (-0.09), AFMD: 8.00 (-0.28), BIND: 5.87 (-0.01), REPH: 8.64 (+0.49), KPTI: 31.44 (-1.61)
Company News for March 17, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:10AM CDT
Companies in the News are: GE,SNI,INO,LTM
INO: 9.09 (-0.36), GE: 25.40 (+0.07), LTM: 70.75 (-0.01), SNI: 71.50 (+1.19)
Inovio Pharmaceuticals (INO) Stock: Weak On High Volume Today
at The Street - Tue Mar 17, 9:05AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a weak on high relative volume candidate
INO: 9.09 (-0.36)
Critical Alerts For Inovio Pharmaceuticals, Kandi Technologies, Skyworks Solutions Released By InvestorsObserver
PR Newswire - Tue Mar 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INO, KNDI, SWKS.
KNDI: 12.47 (-0.55), INO: 9.09 (-0.36), SWKS: 102.05 (+2.48)
Advances in Biotech Expanded Studies Lead to Cutting-Edge Therapeutic Treatments - Company Announces Positive Final Results in Treatment for Alzheimer's Disease
PR Newswire - Tue Mar 17, 7:35AM CDT
The latest medical projects aimed to prevent illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), TG Therapeutics, Inc. (NASDAQ: TGTX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and Actavis plc (NYSE: ACT)
INO: 9.09 (-0.36), ACT: 317.06 (+2.65), LXRX: 1.10 (-0.04), TGTX: 18.22 (-0.60)
Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 1:44PM CDT
INO: 9.09 (-0.36)
Why Inovio Pharmaceuticals Inc. Shot Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 16, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Inovio Pharmaceuticals ...
INO: 9.09 (-0.36), ANAC: 54.24 (-1.88)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 11:45AM CDT
SCON: 1.44 (-0.13), NES: 3.26 (+0.26), ADXS: 12.54 (+0.14), PRTS: 2.30 (+0.06), PFIE: 1.30 (-0.04), MVIS: 3.71 (-0.15), NSLP: 5.75 (+0.31), TRIL: 17.81 (-0.39), VRML: 2.21 (+0.14), DSKY: 7.02 (-0.19), STRL: 4.46 (+0.12), INO: 9.09 (-0.36), ENZ: 3.02 (-0.04), ICEL: 7.71 (-0.39), MTL: 1.15 (-0.12), MSO: 6.27 (+0.08), HELI: 1.30 (+0.03), PKOH: 52.24 (+2.46), OGEN: 1.15 (-0.11), BLPH: 11.10 (+0.32)
Inovio awarded $16M grant to expand HIV strains covered with PENNVAX HIV vaccine
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 9:29AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals (INO) Is Today's Strong On High Volume Stock
at The Street - Mon Mar 16, 9:02AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a strong on high relative volume candidate
INO: 9.09 (-0.36)
Inovio (INO) Posts Narrower-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 7:03AM CDT
Inovio (INO) Posts Narrower-than-Expected Loss in Q4
INO: 9.09 (-0.36)
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases
GlobeNewswire - Mon Mar 16, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company and its academic collaborators, including the University of Pennsylvania (UPenn), were awarded a new five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development Program grant from the National Institute of Allergy and Infectious Diseases (NIAID).
INO: 9.09 (-0.36)
Inovio Pharma ups revenues 47% in Q4
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:50AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 5:43AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 16, 5:30AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
INO: 9.09 (-0.36)
Will Inovio (INO) Disappoint This Earnings Season Again? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 10:20AM CDT
Inovio Pharmaceuticals (INO), which is scheduled to report fourth-quarter 2014 results before the opening bell on Mar 16, had posted a negative earnings surprise of 9.09% in the last quarter.
BDSI: 14.97 (-0.25), INO: 9.09 (-0.36), CPRX: 4.74 (-0.19)
Inovio Pharmaceuticals, Inc. (INO) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:32AM CDT
Inovio Pharmaceuticals, Inc. (INO) was a big mover last session, as the company saw its shares rise more nearly 13% on the day.
INO: 9.09 (-0.36), ACOR: 34.74 (-0.39)
Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day
GlobeNewswire - Thu Mar 19, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Chief Operating Officer, Dr. Niranjan Sardesai, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 at the Metropolitan Club in New York City.
INO: 9.09 (-0.36)
Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development -- Infectious Diseases
GlobeNewswire - Wed Mar 18, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today the appointment of Scott M. White, M.D. as Vice President, Clinical Development - Infectious Diseases. Dr. White will be responsible for advancing Inovio's infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
INO: 9.09 (-0.36)
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 17, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
PCYO: 5.04 (-0.21), INO: 9.09 (-0.36), PRSC: 50.00 (-0.72), GLMD: 13.25 (+1.60), ICEL: 7.71 (-0.39), BDE: 9.99 (+0.17), NERV: 5.98 (-0.09), AFMD: 8.00 (-0.28), BIND: 5.87 (-0.01), REPH: 8.64 (+0.49), KPTI: 31.44 (-1.61)
Company News for March 17, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:10AM CDT
Companies in the News are: GE,SNI,INO,LTM
INO: 9.09 (-0.36), GE: 25.40 (+0.07), LTM: 70.75 (-0.01), SNI: 71.50 (+1.19)
Inovio Pharmaceuticals (INO) Stock: Weak On High Volume Today
at The Street - Tue Mar 17, 9:05AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a weak on high relative volume candidate
INO: 9.09 (-0.36)
Critical Alerts For Inovio Pharmaceuticals, Kandi Technologies, Skyworks Solutions Released By InvestorsObserver
PR Newswire - Tue Mar 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INO, KNDI, SWKS.
KNDI: 12.47 (-0.55), INO: 9.09 (-0.36), SWKS: 102.05 (+2.48)
Advances in Biotech Expanded Studies Lead to Cutting-Edge Therapeutic Treatments - Company Announces Positive Final Results in Treatment for Alzheimer's Disease
PR Newswire - Tue Mar 17, 7:35AM CDT
The latest medical projects aimed to prevent illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), TG Therapeutics, Inc. (NASDAQ: TGTX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and Actavis plc (NYSE: ACT)
INO: 9.09 (-0.36), ACT: 317.06 (+2.65), LXRX: 1.10 (-0.04), TGTX: 18.22 (-0.60)
Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 1:44PM CDT
INO: 9.09 (-0.36)
Why Inovio Pharmaceuticals Inc. Shot Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 16, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Inovio Pharmaceuticals ...
INO: 9.09 (-0.36), ANAC: 54.24 (-1.88)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 11:45AM CDT
SCON: 1.44 (-0.13), NES: 3.26 (+0.26), ADXS: 12.54 (+0.14), PRTS: 2.30 (+0.06), PFIE: 1.30 (-0.04), MVIS: 3.71 (-0.15), NSLP: 5.75 (+0.31), TRIL: 17.81 (-0.39), VRML: 2.21 (+0.14), DSKY: 7.02 (-0.19), STRL: 4.46 (+0.12), INO: 9.09 (-0.36), ENZ: 3.02 (-0.04), ICEL: 7.71 (-0.39), MTL: 1.15 (-0.12), MSO: 6.27 (+0.08), HELI: 1.30 (+0.03), PKOH: 52.24 (+2.46), OGEN: 1.15 (-0.11), BLPH: 11.10 (+0.32)
Inovio awarded $16M grant to expand HIV strains covered with PENNVAX HIV vaccine
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 9:29AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals (INO) Is Today's Strong On High Volume Stock
at The Street - Mon Mar 16, 9:02AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a strong on high relative volume candidate
INO: 9.09 (-0.36)
Inovio (INO) Posts Narrower-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 7:03AM CDT
Inovio (INO) Posts Narrower-than-Expected Loss in Q4
INO: 9.09 (-0.36)
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases
GlobeNewswire - Mon Mar 16, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company and its academic collaborators, including the University of Pennsylvania (UPenn), were awarded a new five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development Program grant from the National Institute of Allergy and Infectious Diseases (NIAID).
INO: 9.09 (-0.36)
Inovio Pharma ups revenues 47% in Q4
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:50AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 5:43AM CDT
INO: 9.09 (-0.36)
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 16, 5:30AM CDT
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
INO: 9.09 (-0.36)
Will Inovio (INO) Disappoint This Earnings Season Again? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 10:20AM CDT
Inovio Pharmaceuticals (INO), which is scheduled to report fourth-quarter 2014 results before the opening bell on Mar 16, had posted a negative earnings surprise of 9.09% in the last quarter.
BDSI: 14.97 (-0.25), INO: 9.09 (-0.36), CPRX: 4.74 (-0.19)
